← back to search

Matthew Hickman

University of Bristol · GB
Area of research
Epidemiology · Hepatology
Research interest
Research interests include HIV, Drug Use, Sexual Risk, Hepatitis C virus research, Substance Abuse Treatment and Outcomes, and Opioid Use Disorder Treatment.
h-index
101
citations
45,539
works
974
NIH funding
primary concept
email

Recent publications

The global epidemiology of injecting drug use, HIV, viral hepatitis and tuberculosis among people who are incarcerated: a multistage systematic review
International Journal of Drug Policy 2026cited by 2position: contributordoi
Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review
International Journal of Drug Policy 2026cited by 1position: contributordoi
Dynamic shifts in crystal methamphetamine and heroin price and purity in metropolitan Melbourne and rural Victoria, Australia, 2009-2020.
2026cited by 0position: contributordoi
Commentary on Dowd et al.: Beyond single data sources-Consistency checking and evidence synthesis for prevalence estimation.
2026cited by 0position: contributordoi
Initiation, cessation and resumption of attendance at the Melbourne supervised injecting room among a cohort of people who inject drugs.
2026cited by 0position: contributordoi
Staff perspectives on implementing opt-out blood-borne virus testing in English emergency departments: a qualitative study.
2026cited by 0position: contributordoi
Estimating incidence rates of primary infection and reinfection with hepatitis C virus among people who inject drugs in Scotland: a model-based analysis of repeated cross-sectional survey data.
2026cited by 0position: contributordoi
Optimal provision of opioid agonist therapy (OAT) and needle and syringe programmes (NSP): a realist evaluation.
2026cited by 0position: contributordoi
Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysis.
2026cited by 0position: contributordoi
Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan.
2026cited by 0position: contributordoi
Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey.
2026cited by 0position: contributordoi
The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling.
2026cited by 0position: contributordoi
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis.
2025cited by 15position: contributordoi
A qualitative study of benzodiazepine/z-drug and opioid co-use patterns and overdose risk.
2025cited by 9position: contributordoi
Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study.
2025cited by 7position: contributordoi
Association of volatile substance, nitrous oxide and alkyl nitrate use with mental health in UK adolescents.
2025cited by 4position: contributordoi
Motivations underlying co-use of benzodiazepines and opioids in the UK: a qualitative study.
2025cited by 2position: contributordoi
Quantifying the impact of a large-scale opioid agonist treatment program on suicide prevention in New South Wales, Australia: A data-modeling study.
2025cited by 2position: contributordoi
Modeling the Potential Health, Health Economic, and Health Inequality Impact of a Large-Scale Rollout of the Drink Less App in England.
2025cited by 2position: contributordoi
Evaluating the effectiveness of the Drink Less smartphone app for reducing alcohol consumption compared with usual digital care: a comprehensive synopsis from a 6-month follow-up RCT.
2025cited by 2position: contributordoi
Risk Factors for Hepatitis C Virus Among the General Population in Sub‐Saharan Africa—An Analysis of Systematic Review Data
Journal of Viral Hepatitis 2025cited by 2position: middledoi
Delineating trajectories of alcohol consumption and alcohol problems from adolescence to young adulthood: An integrated assessment of genetic, familial, and psychosocial factors.
2025cited by 1position: contributordoi
Childhood conduct problems, potential snares in adolescence, and problematic substance use in Brazil.
2025cited by 1position: contributordoi
Estimating Prevalence and Number of People With Chronic Hepatitis B: A Multiplier Method Based on Public Health Surveillance Data in UK (2015-2021).
2025cited by 1position: contributordoi
Pilot postal birth cohort hepatitis C virus screening in UK primary care: HepCAPP study.
2025cited by 1position: contributordoi
Identifying key risk factors for intentional self-harm, including suicide, among a cohort of people prescribed opioid agonist treatment: A predictive modelling study.
2025cited by 1position: contributordoi
Suicide in people prescribed opioid-agonist therapy in Scotland, United Kingdom, 2011-2020: A national retrospective cohort study.
2025cited by 1position: contributordoi
Has the HCV cascade of care changed among people who inject drugs in England since the introduction of direct-acting antivirals?
2025cited by 1position: contributordoi
Characterising benzodiazepine use and the association with non-fatal overdose among people who inject opioids in England, Wales and Northern Ireland.
2025cited by 0position: contributordoi
Risk prediction models for targeted testing of HIV, hepatitis B and hepatitis C: a systematic review and meta-analysis.
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Peter Vickerman · At Bristol124 papers (2012–2026) · 97 papers (2019–2026)Louisa Degenhardt · UNSW Sydney41 papers (2012–2026)Sharon Hutchinson · University of Antwerp40 papers (2013–2026)Jon Heron · NHS England34 papers (2019–2023)Natasha K. Martin · University of California System33 papers (2012–2022)Michael Farrell · Arizona State University25 papers (2017–2026)John Dillon · Mayo Clinic23 papers (2013–2026)Adam Trickey · King's College London23 papers (2019–2026)Natasha K. Martin · University of California System21 papers (2019–2025)Marcus R Munafò · UK Centre for Tobacco & Alcohol Studies20 papers (2019–2025) · 20 papers (2019–2026)Amy Peacock · Mercy Hospital19 papers (2019–2026)Colin Angus · University of Sheffield17 papers (2015–2025) · 17 papers (2019–2026)Jason Grebely · UNSW Sydney16 papers (2012–2020)Jason Grebely · Data6115 papers (2019–2026)Janni Leung · National Centre for Clinical Research on Emerging Drugs14 papers (2019–2023)Josephine G Walker · Orange County School14 papers (2019–2026)Behzad Hajarizadeh · UNSW Sydney13 papers (2020–2026)